Agios Pharmaceuticals (AGIO) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 28.0% versus a loss of 25.1%. Over five years, XERS leads with a +424.0% price change compared with -31.0% for AGIO. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $1.90 billion), about 1.0 times the size, while Agios Pharmaceuticals is growing revenue faster (+48.0% vs +43.7%).
Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -764.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | XERS |
|---|---|---|
| Share price | $31.81 | $10.48 |
| Market cap | $1.90B | $1.91B |
| 1-day change | -0.34% | +2.85% |
| YTD return | +17.27% | +33.50% |
| 1-year return | -25.07% | +27.96% |
| 5-year return | -31.03% | +424.00% |
| Forward P/E | — | 28.32 |
| EPS (TTM) | $-7.01 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | $291.85M |
| Revenue growth (YoY) | +48.03% | +43.72% |
| Net income (latest FY) | $-412.78M | $554.00K |
| Gross margin | 88.26% | 85.41% |
| Operating margin | -873.87% | 8.53% |
| Net margin | -764.01% | 0.19% |
| 52-week high | $46.00 | $11.33 |
| 52-week low | $22.24 | $5.25 |
| Distance from 52-week high | -30.85% | -7.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +44.61% | +22.71% |
| Average volume | 1.08M | 2.17M |
| Shares outstanding | 59.70M | 182.32M |
| Employees | 539 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed AGIO by 53.0 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
AGIO vs XERS FAQ
Which is bigger, Agios Pharmaceuticals or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $1.90B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or XERS?
XERS returned +27.96% over the past 12 months, compared with -25.07% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.